NCT00881049View on ClinicalTrials.gov

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Metastatic Melanoma
Interventions
DRUG

Imatinib (Gleevec)

Imatinib will be given for enrolled patients to investigate efficacy and safety

Trial Locations (1)

10036

Beijing Cancer Hospital, Beijing

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Peking University

OTHER

NCT00881049 - Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter